These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8562409)

  • 1. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.
    Lokhorst HM; Sonneveld P; Wijermans PW; van Marwijk Kooy M; Meuwissen OJ; van Oers RH; van der Griend R; Dekker AW
    Br J Haematol; 1996 Jan; 92(1):44-8. PubMed ID: 8562409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
    Raina V; Sharma A; Kumar R; Bhargava M
    Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma.
    Ossenkoppele GJ; Schuurhuis GJ; Jonkhoff AR; van der Hem KG; Legdeur MC; Boot-Bakker A; Westra AH; Dräger AM; Huijgens PC
    Eur J Cancer; 1996 Nov; 32A(12):2058-63. PubMed ID: 9014745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma.
    Bishton M; Gilyead M; Das Gupta E; Williams C; Russell NH; Byrne JL
    Leuk Res; 2007 Aug; 31(8):1063-8. PubMed ID: 17324463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone.
    Kröger N; Zeller W; Hassan HT; Krüger W; Renges H; Hummel K; Gutensohn K; Lölliger C; Zander AR
    Ann Hematol; 1998 Jun; 76(6):257-62. PubMed ID: 9692813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
    Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
    Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma.
    Goldschmidt H; Hegenbart U; Wallmeier M; Hohaus S; Engenhart R; Wannenmacher M; Haas R
    Ann Oncol; 1997 Mar; 8(3):243-6. PubMed ID: 9137792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment.
    Knudsen LM; Rasmussen T; Jensen L; Johnsen HE
    Med Oncol; 1999 Dec; 16(4):245-54. PubMed ID: 10618687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
    Clark AD; Douglas KW; Mitchell LD; McQuaker IG; Parker AN; Tansey PJ; Franklin IM; Cook G
    Br J Haematol; 2002 Jun; 117(3):605-12. PubMed ID: 12028028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
    Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
    Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.
    Badros A; Barlogie B; Siegel E; Morris C; Desikan R; Zangari M; Fassas A; Anaissie E; Munshi N; Tricot G
    Br J Haematol; 2001 Sep; 114(3):600-7. PubMed ID: 11552985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.